Did You Know...
...that the inventor of the electric motor was a blacksmith named Thomas Davenport? Described as "a brilliantly unsuccessful inventor", Davenport invented the first rotary electric motor. In 1836 he headed out -- on foot -- from his Vermont home to file a patent application at the Patent Office in Washington, D.C. By the time he got there, he had squandered away his money and couldn't afford the $30 filing fee so he turned around and went home. When he later mailed in his application with money he'd raised, the Patent office was destroyed in a fire. He did finally get credit for his invention on Feb. 5, 1837.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7427591 | Suppression of immune response via inhibition of cathepsin S Methods and products for suppressing a class II MHC-restricted immune response in a mammal, or in mammalian cells, are described. The methods depend upon inhibiting invariant chain proteolysis by cathepsin S from class II MHC/invariant chain complexes, thereby reduc... | 09/23/2008 |
| 7425332 | Treatment of autoimmune conditions with Copolymer 1 and related Copolymers The present invention is directed to polypeptides containing at least three amino acids randomly joined in a linear array; wherein at least one of the three amino acids is an aromatic amino acid, at least one of the three amino acids is a charged amino acid and at l... | 09/16/2008 |
| 7419663 | Treatment of complement-associated disorders The present invention concerns a recently discovered macrophage specific receptor, STIgMA, and its use in the treatment of complement-associated disorders. ... | 09/02/2008 |
| 7402430 | MHC class II antigen-presenting systems and methods for activating CD4T cells The present invention relates to synthetic antigen-presenting matrices, their methods of making and their methods of use. One such matrix is cells that have been transfected to produce MHC antigen-presenting molecules with one or more accessory molecules. The matric... | 07/22/2008 |
| 7399471 | Polypeptides capable of forming antigen binding structures with specificity for the Rhesus D antigens, the DNA encoding them and the process for their preparation and use Polypeptides capable of forming antigen binding structures specific for Rhesus D antigens include the sequences indicated in the FIGS. 1a to 16b. The obtained polypeptides, being Fab fragments, MAY be used directly as an active ingredient... | 07/15/2008 |
| 7399741 | Notch The present invention relates to the use of therapeutic compounds in the modification of T-cell, T-cell-antigen presenting cell (APC) interactions and the interactions between pathogenic organisms and immunocompetent cells of a host. In particular it relates to the ... | 07/15/2008 |
| 7390490 | Uses of anti-CX3CR1 antibody, anti-fractalkine antibody and fractalkine There are provided uses of an antibody directed to CX3CR1 and fractalkine. Killer lymphocytes can be readily identified, eliminated and separated by using an anti-CX3CR1 antibody. Further, there can be provided an antibody drug for suppressing chemotaxis and cytotox... | 06/24/2008 |
| 7368542 | Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions The binding specificity of at least one plasma protein suspended or dissolved in a liquid medium is altered by exposing the protein to an oxidizing agent or an electric current sufficient to alter its binding specificity. A masked protein such as an autoantibody can... | 05/06/2008 |
| 7285524 | Allo and auto-reactive T-cell epitopes The present invention relates to a pharmaceutical composition for the prevention of alloimmunization of a subject or the immunosuppression of a response elicited by alloimmunization of a subject or an autoimmune haemolytic disease for said composition comprising an ... | 10/23/2007 |
| 7285525 | Suppression of immune response via inhibition of cathepsin S Methods and products for suppressing a class II MI-IC-restricted immune response in a mammal, or in mammalian cells, are described. The methods depend upon inhibiting invariant chain proteolysis by cathepsin S from class II MHC/invariant chain complexes, thereby red... | 10/23/2007 |
| 7279172 | Treatment of autoimmune conditions with copolymer 1 and related copolymers The present invention provides heteropolymer compositions and peptide compositions, and methods of making and using therapeutic compositions comprising amino acid heteropolymers for treatment of a subject for an autoimmune or an inflammatory disease, the heteropolym... | 10/09/2007 |
| 7279158 | Methods for the treatment of inflammatory joint disease The use of compounds that block complement component C5 or its active fragments C5a and/or C5b (such compounds collectively referred to as “C5 blockers”) to treat established joint inflammation (arthritis) is disclosed. Administration of such C5 bl... | 10/09/2007 |
| 7264799 | Use of heparinases to decrease inflammatory response Heparinase enzymes can be used as a medical treatment to reduce localized inflammatory responses. Treatment of activated endothelium with heparinase inhibits leukocyte rolling, adhesion and extravasation. Most of the heparin and heparan sulfate on endothelial cell s... | 09/04/2007 |
| 7256254 | Methods of preparation and composition of peptide constructs useful for treatment of autoimmune and transplant related host versus graft conditions Peptide constructs including a first peptide segment which includes an amino acid sequence associated with autoimmune disease, asthma, allergy or xeno- or allograft transplantation rejections bonded directly or via a linker or spacer to a second peptide which binds ... | 08/14/2007 |
| 7244431 | Allergy vaccines and their preparation The present invention relates to a pharmaceutical composition containing a peptide and a pharmaceutically acceptable carrier or diluent wherein the peptide has a length of 8 to 50 amino acids, at least three preferably consecutive amino acids of the peptide are iden... | 07/17/2007 |
| 7208156 | Composition for inducing humoral anergy to an immunogen comprising a T cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic valency platform molecule Conjugates of nonimmunogenic valency platform molecules and analogs of immunogens that possess the specific B cell binding ability of the immunogen but lack T cell epitopes and which, when introduced into individuals, induce humoral anergy to the immunogen are discl... | 04/24/2007 |
| 7163683 | Composition for inducing humoral anergy to an immunogen comprising a T cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic valency platform molecule Conjugates of nonimmunogenic valency platform molecules and analogs of immunogens that possess the specific B cell binding ability of the immunogen but lack T cell epitopes and which, when introduced into individuals, induce humoral anergy to the immunogen are discl... | 01/16/2007 |
| 7098248 | Beta-adrenergic blockade reversal of catabolism after severe burn Provided herein is a method of method of treating an individual having a severe burn, comprising the step of administering to said individual a pharmacologically effective dose of a beta-adrenergic antagonist. ... | 08/29/2006 |
| 7060274 | Receptor specific transepithelial transport of therapeutics The present invention relates in general to methods and products for initiating an immune response against an antigen, and in particular relates to transepithelial delivery of antigens to provoke tolerance and immunity. The present invention further relates to metho... | 06/13/2006 |
| 7041289 | Method for treating established spontaneous auto-immune diseases in mammals A method of treating spontaneous and ongoing auto-immune diseases in mammals, comprising administering to a mammal, in need of such a treatment, a therapeutically effective amount of one or more non mitogenic anti-CD3 active principles to achieve permanent disease r... | 05/09/2006 |
| 7025960 | Use of beta-glucuronidase not in combination with allergens for the preparation of medicaments for the treatment of immune or allergic diseases The use of beta-glucuronidase not in combination with allergens for the preparation of medicaments for the treatment of immune or allergic diseases is disclosed. ... | 04/11/2006 |
| 7022322 | treatment of cardiomyopathy by removal of autoantibodies Immunoapheresis treatment for cardiomyopathy comprises passing the patient's plasma over a column having coupled thereto a specific ligand for human immunoglobulin, thereby removing a significant portion of the immunoglobulin from the patient's plasma, and then rein... | 04/04/2006 |
| 6979450 | Method and compositions for detection and diagnosis of infectious diseases Methods and compositions for the detection and diagnosis of infectious diseases are provided. In particular, efficient and sensitive methods and compositions for the detection of active mycobacterial disease are provided for distinguishing between individuals having... | 12/27/2005 |
| 6979442 | Stabilized protein compositions This invention relates to stabilized protein compositions, methods for preparing such stabilized protein compositions, dosage forms for administering such stabilized protein compositions to mammals and methods for preventing or treating infections in mammals by admi... | 12/27/2005 |
| 6953578 | Materials and methods for detection and treatment of immune system dysfunctions The subject invention concerns novel materials and methods for the treatment and/or prevention of autoimmune disease. In a specific embodiment, elevated production of prostaglandin synthase-2 (PGS-2) is correlated with autoimmune dysfunction. ... | 10/11/2005 |
| 6932969 | Ig fractions having immunomodulatory activity The invention concerns a method for preparing Ig fractions from human polyvalent intravenous Immunoglobulins (IV Ig) which are in particular likely to be responsible for the immunomodulatory effect observed during the treatment of certain autoimmune diseases. The in... | 08/23/2005 |
| 6818217 | Immunoreactive peptides The present invention relates generally to molecules such as peptides, polypeptides and proteins which interact immunologically with antibodies or T-cells in subjects having pre-clinical or clinical Insulin-Dependent Diabetes Mellitus (IDDM). These molecules are pre... | 11/16/2004 |
| 6800300 | Method for treating autoimmune and alloimmune diseases Disclosed is a method for treating a mammalian subject suffering from an autoimmune or alloimmune disease by administering to the subject a drug treatment which results in at least partial remission of one or more symptoms of the autoimmune or alloimmune disease, an... | 10/05/2004 |
| 6790450 | Use of coxiella bacteria to treat autoimmune disease Therapeutic compositions including a species of Coxiella or one or more antigenic components therefrom or analogous or homologous components thereof are disclosed. These compositions are useful in preventing, inhibiting, delaying onset of or otherwise ameliorating t... | 09/14/2004 |
| 6773695 | Modulation of allergic response The modulation or elimination of an allergic condition according to the invention can be achieved by injecting small amounts of allergen directly into a lymph node, which greatly reduces the potential for side effects. ... | 08/10/2004 |
| 6759037 | Compositions and methods for treating diabetes The present invention provides an isolated population of cells containing an expressible nucleic acid encoding proinsulin containing a proinsulin cleavage site and a glucose-regulated expressible nucleic acid encoding a protease capable of cleaving the proinsulin cl... | 07/06/2004 |
| 6696061 | Immunomodulatory peptides A purified preparation of a peptide consisting essentially of an amino acid sequence identical to that of a segment of a naturally-occurring human protein, said segment being of 10 to 30 residues in length, inclusive, wherein said peptide binds to a human... | 02/24/2004 |
| 6649165 | Method of blocking cytotoxic activity in patients with amyotrophic lateral sclerosis using soluble FcγRIII receptors The present invention is directed to a method of blocking the cytotoxic activity of FcγRIII receptor-positive immune cells in a patient with amyotrophic lateral sclerosis using an effective amount of soluble FcγRIII receptors. The soluble FcγRIII recep... | 11/18/2003 |
| 6632664 | Avian infectious herpesvirus recombinants and recombinant vaccines prepared with the use of the same An avian infectious recombinant herpesvirus is prepared by inserting a foreign gene, in particular a heterologous antigen gene, into an insertion site in an untranslated genetic region in the genome. A chicken vaccine comprising such a recombinant virus i... | 10/14/2003 |
| 6632440 | Methods and compounds for the treatment of mucus hypersecretion A method of treating mucus hypersecretion, the causative factor in chronic obstructive pulmonary disease (COPD), asthma and other clinical conditions involving COPD, comprises administering a compound that inhibits exocytosis in mucus secreting cells or n... | 10/14/2003 |
| 6627194 | Activated immunoglobulin Activated immunoglobulin which is useful as an eosinophilia-suppressing agent, immunomodulating agent, therapeutic agent for autoimmune diseases, anfiinflammatory agent and antiallergic agent is obtained by admixing immunoglobulin with a histamine compone... | 09/30/2003 |
| 6579688 | Stabilizing diluent for polypeptides and antigens Compositions for stabilizing polypeptides or antigens are described. These compositions are useful for stabilizing polypeptides or antigens stored in aqueous formulations. Such formulations can be used for various analytical or other methods.... | 06/17/2003 |
| 6569467 | Treatment of autoimmune diseases An autoimmune vaccine is provided for administration to human patients to alleviate the symptoms of autoimmune diseases such as rheumatoid arthritis. The vaccine comprises an aliquot of the patient's blood, containing, inter alia, leukocytes having upregu... | 05/27/2003 |
| 6566386 | Immunomodulating and antiinflammatory agent In the present invention, pharmaceutical compositions containing a histamine-added gamma-globulin as an effective component are used as an immunomodulating agent, a suppressive agent for eosinophilia, and as an antiinflammatory agent. The immunomodulating... | 05/20/2003 |
| 6551593 | Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through 4 ଲ 7 and its ligands and madcam The invention relates to the treatment of individuals suffering from a disease associated with leukocyte recruitment to the gastrointestinal tract or other tissues as a result of binding of leukocytes to gut-associated endothelium expressing the molecule ... | 04/22/2003 |
